An interventional study of probiotic (GKB7/placebo) in Autism Spectrum Disorder, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Autism Spectrum Disorder by National Taiwan University Hospital — 14 open to participants now, 16 under way, none of them phase 3. Autism Spectrum Disorder · National Taiwan University Hospital.
Among the 42 studies in Autism Spectrum Disorder by National Taiwan University Hospital, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2024, is one of 20 with no phase, reaches primary completion later than 7 of the 15 other live ones, and was the 33rd registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →14 of the 42 studies in Autism Spectrum Disorder by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 4–10
National Taiwan University Hospital · Sites in Taiwan
Ages 4–10
National Taiwan University Hospital · Sites in Taiwan
Ages 3–11
National Taiwan University Hospital · Sites in Taiwan
Ages 18–50
National Taiwan University Hospital · Sites in Taiwan
Ages 11–20
By country, each count listing its studies:
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 4 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2024.
This study's planned enrollment of 110 is above the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 55 across the 20 interventional studies, 249 across the 22 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
3 of the studies in Autism Spectrum Disorder by National Taiwan University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07775937National Taiwan University HospitalSocial Robots and Board Games for Children With Autism Spectrum Disorder | 2026-11-30 |
| NCT06677840National Taiwan University HospitalExploring the Gut-Brain-Behavior Axis With Biomarkers, Probiotic Efficacy, and Artificial Intelligence Algorithms | 2027-04-30 |
| NCT05857813National Taiwan University HospitalSocial Skills Training Group Effectiveness in Adolescents With Autism Spectrum Disorder | 2027-07-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Autism Spectrum Disorder by National Taiwan University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With an increased prevalence of autism spectrum disorder (ASD) worldwide and in Taiwan, ASD demands urgent attention due to its lasting impact, unclear causes, and limited diagnostic and treatment options. Recent studies highlight disruptions in the gut-brain axis, particularly in ASD. Building on PI Gau's prior research on altered gut microbiota in autism spectrum disorder (ASD), this proposed 4-year study aims to develop evidence-based probiotic intervention (GKB7) and treatment biomarkers for behavioral interventions (Naturalistic Developmental Behavioral Interventions, NDBI, and Program for the Education and Enrichment of Relational Skills, PEERS®) through comprehensive assessments. The ultimate goal is to establish probiotic treatments and diagnostic/treatment biomarkers for ASD utilizing a deep-learning multimodal auxiliary platform.
Specific Aims:
S.I To conduct a randomized, double-blind, placebo-controlled trial to assess the treatment effects of Clostridium butyricum GKB7 on ASD.
S.II To investigate the effect of NDBI intervention trials using metagenomics as the outcome measure.
S.III To evaluate the effect of PEERS® interventional trials with metagenomics as the outcome measure.
S.IV To develop an artificial intelligence (machine/deep learning) multimodal auxiliary prediction platform that integrates environmental, behavioral/clinical, neurocognitive/imaging, and metagenomic data for ASD diagnosis, subtyping, and impairment prediction.
S.V To identify microbiome and metabolomic biomarkers and endophenotypes of ASD, and to establish Gut-Brain-Behavioral Axes in ASD.
We will enroll 110 ASD patients (age 4-15 years) in probiotic clinical trials with Clostridium butyricum GKB7 (S.I), 120 ASD children (2-6 years old) in treatment biomarker of NDBIs study (S.II), and 24 autistic adolescents and 15 young adults in treatment biomarker of PEERS® study (S.III). Assessments include diagnostic evaluations and dimensional measures regarding ASD and other diagnoses (ADI-R, ADOS, K-SADS-E, CGI), digestive symptoms and eating (GSQ, FFQ), autistic symptoms (SRS, CAST, GSQ, SP, EQ, SCQ), psychopathology (CBCL, SNAP-IV), social functions/quality of life (SAICA), neuropsychological functions (CPT, CANTAB, BRIEF), images (fNIRS, T1, T2, rfMRI, DTI, MRS), metabolome (blood) and microbiome (stool). We will conduct multidimensional data analysis to identify the mutual regulation pathways of the gut-brain-behavior axis and key biochemical molecules using machine/deep learning algorithms to establish a multimodal auxiliary platform for ASD classification and prediction (S.IV). We will also use the case-control and longitudinal data to identify microbiota and metabolomics biomarkers and endophenotypes of ASD (S.V).
S.I.1 Pilot Study-Open-Label in 20 autistic children: This pilot clinical trial will employ an open-label study design to explore the effects of a 12-week treatment with the probiotic Clostridium butyricum GKB7 on clinical symptoms as primary outcome, and cognitive function, brain activity, and gut microbiota as secondary outcome measures in 20 autistic children, aged 4-15 years. Participants and their parents will undergo clinical and neuropsychological assessments at baseline, Month 1, Month 2, and Month 3 or the last observation day. MRI scans, and stool and blood samples will be collected at baseline and at Month 3 or the last observation day SI.2 Double-Blind Randomized Placebo-Controlled Trial in 90 autistic children: The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5. They will be randomized to two treatment arms [GKB7, n = 60; the placebo comparison group, n = 30] for three months followed by another 3-month open-label clinical trial as follows. At the end of 3rd month, all the 90 participants will receive continuous treatment with GKB7 for 3 months. In summary, among the 90 ASD participants, 60 will receive GKB7 for 6 months, 30 will have routine follow-up assessments for three months, followed by GKB7 for 3 months. The participants and their parents will receive clinical and neuropsychological assessments at baseline (before treatment, V0), month 1 (V1), month 2 (V2), month 3 (V3, transition to open-label study), month 4 (V4), and month 6 (V5). Besides, the participants will undergo MRI scanning, blood and stool sampling at baseline (before treatment, V0), month 3 (V3), and month 6 (V5).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: probiotic (GKB7/placebo)
Other: probiotic (GKB7/placebo)
The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5
Clinical Global Impression
The CGI-S (Clinical Global Impression-Severity Scale) and CGI-I (-Improvement Scale) are single-item ratings of the clinician's assessment of the global severity of clinical symptoms. Severity and improvement are rated on a 7-point scale (from 1 = normal, not at all ill, to 7 = among the most extremely ill) and (from 1 = very much improved, to 7 = very much worse).
Time frame: At baseline (before treatment, V0), month 1 (V1), month 2 (V2), month 3 (V3), month 4 (V4), and month 6 (V5)
Social Responsiveness Scale (SRS)
The SRS is a 65-item questionnaire based on parent-reports on the child's social interactions with others (rating 0-3), consists of 5 subscales: social awareness, social cognition, social communication, social motivation, and autistic mannerisms
Time frame: At baseline (before treatment, V0), month 1 (V1), month 2 (V2), month 3 (V3), month 4 (V4), and month 6 (V5)
Self-administered questionnaires
The self-administered questionnaires include autistic symptoms (Autism Spectrum Quotient, AQ; Sensory Profile, SP), psychopathology (Child Behavior Checklist, CBCL; Swanson, Nolan, and Pelham, version IV scale, SNAP-IV), social functions/quality of life (Social Adjustment Inventory for Children and Adolescents, SAICA), and executive functions (Behavior Rating Inventories of Executive Function, BRIEF)
Time frame: At baseline (before treatment, V0), month 3 (V3), and month 6 (V5)
Neuropsychological functions: Continuous Performance Test(CPT)
The 4 dimensions of CCPT: focused attention, hyperactivity/impulsivity, sustained attention, and vigilance
Time frame: At baseline (before treatment, V0), month 3 (V3), and month 6 (V5)
Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries(CANTAB)
The 4 main cognitive components of CANTAB: Visual Memory, Attention, Working and Planning Memory (Executive Functions), and Decision Making
Time frame: At baseline (before treatment, V0), month 3 (V3), and month 6 (V5)
Started May 2024 (actual). Primary completion is estimated for Apr 2027, 35 months after the start.
Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 35 months is above that.
Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →